Provided by Tiger Fintech (Singapore) Pte. Ltd.

NanoViricides

1.27
-0.0067-0.52%
Volume:8.38K
Turnover:10.76K
Market Cap:19.92M
PE:-1.78
High:1.30
Open:1.28
Low:1.27
Close:1.28
Loading ...

NanoViricides, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference, May 14th, NYC

Newsfile
·
05 May

Measles is Likely to Become Endemic - NanoViricides Is Testing a Drug to Combat It

ACCESS Newswire
·
29 Apr

NanoViricides Inc: Begun Evaluation of Its Clinical Drug Nv-387 for Treatment of Measles Virus

THOMSON REUTERS
·
14 Apr

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company

ACCESS Newswire
·
11 Mar

Measles Outbreak: NV-387 Promises To Be An Effective Drug To Treat Patients; We are Ready To Work With HHS, Says NanoViricides President Dr. Anil Diwan

ACCESS Newswire
·
04 Mar

NanoViricides reports Q2 EPS (14c) vs. (18c) last year

TIPRANKS
·
19 Feb

NanoViricides, Inc. Has Filed its Quarterly Report

ACCESS Newswire
·
19 Feb

NanoViricides: Fiscal Q2 Earnings Snapshot

Associated Press Finance
·
15 Feb

Is NanoViricides Inc. (NNVC) the Best Nanotech Penny Stock to Invest In?

Insider Monkey
·
15 Feb

NanoViricides Drug Can Fight Bird Flu Pandemic; H5N1 Virus Cannot Escape

ACCESS Newswire
·
11 Feb

NanoViricides to Present at the MicroCap Conference on Wednesday, January 29, 2025

ACCESS Newswire
·
29 Jan

NanoViricides Inc: Engages Cro for Phase Ii Clinical Trial

THOMSON REUTERS
·
27 Jan

NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025

ACCESSWIRE
·
13 Jan

Multiple Viral Threats Amplify Call for Preparedness with Broad-Spectrum Antivirals

ACCESSWIRE
·
08 Jan

NanoViricides is in a Great Position to Fight Potential Bird Flu Pandemic with a Drug that the Mercurial H5N1 Influenza A Virus is Unlikely to Escape

ACCESSWIRE
·
23 Dec 2024

NanoViricides, Inc. Has Filed Its Quarterly Report: Broad-spectrum Antiviral NV-387 Progressing to Phase II Clinical Trial - Multiple Indications of NV-387 Include MPOX/Smallpox, RSV, Influenza, COVID

ACCESSWIRE
·
15 Nov 2024

NanoViricides: Fiscal Q1 Earnings Snapshot

Associated Press Finance
·
15 Nov 2024